Radiation-Free Advantage Micrima’s CE-marked Mi~Scan and Mi~Score offer breast density measurement and cancer risk assessment without ionising radiation or breast compression, presenting a compelling value proposition for hospitals, clinics, and employers seeking safer, patient-friendly screening options.

UK International Growth With ongoing UK deployment and stated international accessibility, target NHS trusts, private clinics, and international partners to scale radiation-free risk profiling, leveraging partnerships with employers and researchers to broaden adoption.

Risk Profiling Demand The personalised 5-year, 10-year and lifetime risk assessments create cross-sell opportunities to integrate with existing breast clinics, genetic counseling services, and preventive health programs in both public and private sectors.

Clinical Validation A two-decade development effort supported by a 1,000-patient trial and ongoing clinical collaborations provides a strong evidence base to engage key clinical champions and payers around cost-effective, radiation-free screening.

Funding & Partnerships Recent funding history and strategic partnerships indicate readiness for co-development and pilot programs with healthcare providers, employers, and research institutions to expand access and generate real-world efficacy data.